CN107252474A - 用于减少夜间排尿的去氨加压素 - Google Patents
用于减少夜间排尿的去氨加压素 Download PDFInfo
- Publication number
- CN107252474A CN107252474A CN201710490960.4A CN201710490960A CN107252474A CN 107252474 A CN107252474 A CN 107252474A CN 201710490960 A CN201710490960 A CN 201710490960A CN 107252474 A CN107252474 A CN 107252474A
- Authority
- CN
- China
- Prior art keywords
- dosage
- night
- minirin
- baseline
- urination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027939 micturition Effects 0.000 title claims abstract description 118
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title claims abstract description 96
- YNKFCNRZZPFMEX-XHPDKPNGSA-N desmopressin acetate trihydrate Chemical compound O.O.O.CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 YNKFCNRZZPFMEX-XHPDKPNGSA-N 0.000 title claims abstract description 92
- 229940028441 minirin Drugs 0.000 title claims abstract description 92
- 230000009467 reduction Effects 0.000 claims abstract description 45
- 210000002700 urine Anatomy 0.000 claims description 82
- 239000003513 alkali Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 16
- 239000006185 dispersion Substances 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 86
- 230000006872 improvement Effects 0.000 abstract description 2
- 230000008859 change Effects 0.000 description 78
- 229940068196 placebo Drugs 0.000 description 71
- 239000000902 placebo Substances 0.000 description 71
- 230000007958 sleep Effects 0.000 description 58
- 230000000422 nocturnal effect Effects 0.000 description 53
- 238000011160 research Methods 0.000 description 52
- 208000005346 nocturnal enuresis Diseases 0.000 description 51
- 238000000034 method Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 201000010099 disease Diseases 0.000 description 25
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 22
- 229910052708 sodium Inorganic materials 0.000 description 22
- 239000011734 sodium Substances 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 21
- 208000004880 Polyuria Diseases 0.000 description 20
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 15
- 206010029446 nocturia Diseases 0.000 description 14
- 208000008967 Enuresis Diseases 0.000 description 12
- 206010021036 Hyponatraemia Diseases 0.000 description 12
- 238000012544 monitoring process Methods 0.000 description 12
- 210000003932 urinary bladder Anatomy 0.000 description 12
- 230000004622 sleep time Effects 0.000 description 11
- 241001269238 Data Species 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000003860 sleep quality Effects 0.000 description 9
- 230000002485 urinary effect Effects 0.000 description 9
- 238000011835 investigation Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 206010046543 Urinary incontinence Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 108010004977 Vasopressins Proteins 0.000 description 6
- 102000002852 Vasopressins Human genes 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000000622 irritating effect Effects 0.000 description 6
- 101800001144 Arg-vasopressin Proteins 0.000 description 5
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 5
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 206010021639 Incontinence Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000027288 circadian rhythm Effects 0.000 description 4
- 201000010064 diabetes insipidus Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000001797 obstructive sleep apnea Diseases 0.000 description 4
- 229940072644 pitressin Drugs 0.000 description 4
- 206010036067 polydipsia Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 230000002686 anti-diuretic effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960002845 desmopressin acetate Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 201000008284 inappropriate ADH syndrome Diseases 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010030124 Oedema peripheral Diseases 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960001523 chlortalidone Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 2
- 229960003199 etacrynic acid Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036033 hyponatraemia Effects 0.000 description 2
- 229960004569 indapamide Drugs 0.000 description 2
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000011224 negative regulation of urine volume Effects 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 229960005461 torasemide Drugs 0.000 description 2
- 229960001288 triamterene Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000036318 urination frequency Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000023783 Genitourinary tract disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 206010059240 Lymphostasis Diseases 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 208000028484 Urethral disease Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- -1 desmopressin acetates Chemical class 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010059642 isinglass Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229910052627 muscovite Inorganic materials 0.000 description 1
- JLTCWSBVQSZVLT-UHFFFAOYSA-N n-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxa Chemical compound NCCCCC(C(=O)NCC(N)=O)NC(=O)C1CCCN1C(=O)C1NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSC1.N1C(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 JLTCWSBVQSZVLT-UHFFFAOYSA-N 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/732,161 | 2010-03-25 | ||
| US12/732,161 US20100286045A1 (en) | 2008-05-21 | 2010-03-25 | Methods comprising desmopressin |
| CN2011800154945A CN102821776A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800154945A Division CN102821776A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107252474A true CN107252474A (zh) | 2017-10-17 |
Family
ID=44365354
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710490960.4A Pending CN107252474A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
| CN201911211683.4A Pending CN110898207A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
| CN201610887523.1A Pending CN106924716A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
| CN2011800154945A Pending CN102821776A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911211683.4A Pending CN110898207A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
| CN201610887523.1A Pending CN106924716A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
| CN2011800154945A Pending CN102821776A (zh) | 2010-03-25 | 2011-03-22 | 用于减少夜间排尿的去氨加压素 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20100286045A1 (enExample) |
| EP (3) | EP3006036B1 (enExample) |
| JP (3) | JP6253977B2 (enExample) |
| CN (4) | CN107252474A (enExample) |
| CA (1) | CA2793502A1 (enExample) |
| DK (2) | DK2550007T3 (enExample) |
| ES (2) | ES2708973T3 (enExample) |
| HR (1) | HRP20190104T1 (enExample) |
| HU (1) | HUE027417T2 (enExample) |
| LT (1) | LT3006036T (enExample) |
| PL (2) | PL3006036T3 (enExample) |
| PT (2) | PT2550007E (enExample) |
| RS (1) | RS58224B1 (enExample) |
| SI (1) | SI3006036T1 (enExample) |
| TR (1) | TR201900240T4 (enExample) |
| WO (1) | WO2012001469A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| US20160098530A1 (en) * | 2014-10-07 | 2016-04-07 | David A. DILL | Devices and methods for managing risk profiles |
| CN112912070A (zh) | 2018-10-17 | 2021-06-04 | 日本化学药品株式会社 | 夜间多尿的治疗或预防剂 |
| WO2022103634A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Improved use of cannabinoids in the treatment of epilepsy |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2024211393A2 (en) | 2023-04-04 | 2024-10-10 | Tulex Pharmaceuticals Inc. | Desmopressin oral compositions |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030216302A1 (en) * | 2002-05-15 | 2003-11-20 | Sun Pharmaceutical Industries Limited | Stable aqueous composition of a peptide |
| CN1649615A (zh) * | 2002-05-07 | 2005-08-03 | 凡林有限公司 | 药物制剂 |
| CN1878563A (zh) * | 2003-11-10 | 2006-12-13 | 西摩·H·费恩 | 包含低剂量去氨加压素的药物组合物 |
| CA2724653A1 (en) * | 2008-05-21 | 2009-11-26 | Ferring International Center S.A. | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |
Family Cites Families (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US4285858A (en) | 1979-10-30 | 1981-08-25 | Mt. Sinai School Of Medicine Of The City University Of N.Y. | Vasopressin analogs |
| US4263283A (en) | 1980-05-16 | 1981-04-21 | Ferring Pharmaceuticals, Inc. | Method for prophylaxis and/or treatment of sickle cell disease |
| GB2111423B (en) | 1981-12-02 | 1985-06-26 | Wyeth John & Brother Ltd | Making quick-dissolving pills |
| DE3275121D1 (en) | 1981-12-11 | 1987-02-19 | Wyeth John & Brother Ltd | Process for preparing solid shaped articles |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| SE8306367L (sv) | 1983-11-18 | 1985-05-19 | Ferring Ab | Antidiuretiskt verkande farmaceutiskt preparat |
| US4863737A (en) | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| IE60941B1 (en) | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4878892A (en) | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| DK365389D0 (da) | 1989-07-24 | 1989-07-24 | Fertin Lab As | Antifungalt tyggegummipraeparat |
| US5091186A (en) | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| TW279133B (enExample) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| SE9101022D0 (sv) | 1991-01-09 | 1991-04-08 | Paal Svedman | Medicinsk suganordning |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| CA2070061C (en) | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
| ES2153362T3 (es) | 1991-08-26 | 2001-03-01 | Abbott Lab | Composiciones y procedimientos de administracion sublingual o bucal de agentes terapeuticos. |
| JP2807346B2 (ja) | 1991-12-24 | 1998-10-08 | 山之内製薬株式会社 | 口腔内崩壊製剤及びその製造法 |
| US5298256A (en) | 1992-04-28 | 1994-03-29 | Corint, Ltd. | Desmopressin buccal patch composition |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5343672A (en) | 1992-12-01 | 1994-09-06 | Scherer Ltd R P | Method for manufacturing freeze dried dosages in a multilaminate blister pack |
| CA2090738C (en) | 1993-02-24 | 1996-05-21 | Hema-Quebec | Use of paf |
| SE9300937L (sv) | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
| SE501677C2 (sv) | 1993-06-18 | 1995-04-10 | Ferring Bv | Biologiskt aktiva vasopressinanaloger, farmaceutiska preparat innehållande dem samt deras användning för framställning av läkemedel |
| EP0710243B1 (en) | 1993-06-29 | 2000-06-14 | Ferring B.V. | Synthesis of cyclic peptides |
| PT708657E (pt) | 1993-06-29 | 2001-11-30 | Ferring Bv | Composicoes para administracao nasal de desmopressina |
| US5500413A (en) | 1993-06-29 | 1996-03-19 | Ferring Ab | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
| US5674850A (en) | 1993-12-23 | 1997-10-07 | Ferring Ab | High purity desmopressin produced in large single batches |
| US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| US5985835A (en) | 1993-12-23 | 1999-11-16 | Ferring B.V. | Desmopressin for nocturia, incontinence and enuresis |
| AU692506B2 (en) | 1993-11-17 | 1998-06-11 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
| SE9400918L (sv) | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| FR2720003B1 (fr) | 1994-05-23 | 1998-06-26 | Samsung Electro Mech | Dispositif servant à inciser la peau pour une médication transcutanée. |
| SE518619C2 (sv) | 1994-12-09 | 2002-10-29 | Gs Dev Ab | Komposition för reglerad frisättning innehållande monokaproin |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| IL113459A (en) | 1995-04-23 | 2000-07-16 | Electromagnetic Bracing System | Electrophoretic cuff apparatus |
| US5843016A (en) | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
| TW411277B (en) | 1996-05-13 | 2000-11-11 | Hisamitsu Pharmaceutical Co | Percutaneous tape preparation containing fentanyl |
| GB9612629D0 (en) | 1996-06-17 | 1996-08-21 | Oxford Biosciences Ltd | Method for providing dense particle compositions for use in transdermal particle delivery |
| DE69719761T2 (de) | 1996-06-18 | 2003-12-18 | Alza Corp., Palo Alto | Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten |
| US5763398A (en) | 1996-06-20 | 1998-06-09 | Ferring B.V. | Nasal administration of desmopressin |
| US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| FR2758195B1 (fr) | 1997-01-09 | 1999-02-26 | Sgs Thomson Microelectronics | Coprocesseur d'arithmetique modulaire comprenant deux circuits de multiplication operant en parallele |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US6511974B1 (en) | 1997-07-30 | 2003-01-28 | Wyeth | Tricyclic vasopressin agonists |
| US6194407B1 (en) | 1997-07-30 | 2001-02-27 | American Home Products Corporation | Tricyclic pyrido vasopressin agonists |
| US5932745A (en) | 1997-07-30 | 1999-08-03 | American Home Products Corporation | Process for converting propargylic amine-N-oxides to enaminones |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US20040018241A1 (en) | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
| US6090803A (en) | 1998-07-24 | 2000-07-18 | American Home Products Corporation | Tricyclic vasopressin agonists |
| US7138393B2 (en) | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| GB9827292D0 (en) | 1998-12-12 | 1999-02-03 | Univ Strathclyde | Freeze drying |
| US6406455B1 (en) | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
| US20060025387A1 (en) | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| US6235900B1 (en) | 1999-02-04 | 2001-05-22 | American Home Products Corporation | Tricyclic pyridine N-oxides vasopressin agonists |
| US6344451B1 (en) | 1999-02-04 | 2002-02-05 | American Home Products | Pyrrolobenzodiazepine carboxyamide vasopressin agonists |
| US6620807B1 (en) | 1999-02-04 | 2003-09-16 | Wyeth | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| US6297234B1 (en) | 1999-02-04 | 2001-10-02 | American Home Products Corporation | Arylthiophene vasopressin agonists |
| EP1153616B1 (en) | 1999-02-15 | 2004-12-01 | Sumitomo Pharmaceuticals Company, Limited | Tablets quickly disintegrated in the oral cavity |
| IL144948A0 (en) | 1999-02-18 | 2002-06-30 | Biovalve Technologies Inc | Electroactive pore |
| AR014640A1 (es) | 1999-02-23 | 2001-03-28 | Univ Nac Quilmes | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US7187771B1 (en) | 1999-09-20 | 2007-03-06 | Security First Corporation | Server-side implementation of a cryptographic system |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| GB2355454A (en) | 1999-10-20 | 2001-04-25 | Ferring Bv | Antidiuretic agents |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| CA2396569C (en) | 2000-01-07 | 2010-03-23 | Biovalve Technologies, Inc. | Injection device |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| AT409081B (de) | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| GB0015601D0 (en) | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
| US6348486B1 (en) | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| BR0114909A (pt) | 2000-10-26 | 2004-02-03 | Alza Corp | Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas |
| ES2705729T3 (es) | 2000-11-30 | 2019-03-26 | Valeritas Inc | Sistemas de suministro y medición de fluidos |
| US7931614B2 (en) | 2000-11-30 | 2011-04-26 | Valeritas, Inc. | Injection systems |
| WO2002064193A2 (en) | 2000-12-14 | 2002-08-22 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
| WO2002050584A2 (en) | 2000-12-21 | 2002-06-27 | Biovalve Technologies, Inc. | Microneedle array systems |
| CZ307857B6 (cs) | 2001-03-16 | 2019-07-03 | Alza Corporation | Transdermální náplast pro podávání fentanylu nebo jeho analogu |
| BR0208823A (pt) | 2001-04-12 | 2004-03-09 | Wyeth Corp | Composto, método de tratamento de distúrbios que são remediados ou aliviados pela atividade de agonista de vasopressina em um mamìfero necessitando do mesmo, e, composição farmacêutica |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| JP2004526771A (ja) | 2001-04-12 | 2004-09-02 | ワイス | シクロヘキシルフェニルバソプレッシンアゴニスト |
| GB2391480B (en) | 2002-08-05 | 2007-02-28 | Caretek Medical Ltd | Drug delivery system |
| US7615234B2 (en) | 2001-09-11 | 2009-11-10 | Glide Pharmaceutical Technologies Limited | Drug delivery technology |
| ATE411276T1 (de) | 2001-09-13 | 2008-10-15 | Kissei Pharmaceutical | Kristalle eines hydroxynorephedrinderivats |
| US6723077B2 (en) | 2001-09-28 | 2004-04-20 | Hewlett-Packard Development Company, L.P. | Cutaneous administration system |
| US6893655B2 (en) | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
| MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| DE60233251D1 (de) | 2001-11-16 | 2009-09-17 | Astellas Pharma Inc | 4,4-difluor-1,2,3,4-tetrahydro-5h-1-benzazepinderivate und deren salze |
| AU2003233118B8 (en) | 2002-05-07 | 2009-07-30 | Ferring Bv | Desmopressin in an orodispersible dosage form |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| US20040115167A1 (en) | 2002-09-30 | 2004-06-17 | Michel Cormier | Drug delivery device and method having coated microprojections incorporating vasoconstrictors |
| CN100537573C (zh) | 2002-10-09 | 2009-09-09 | 东丽株式会社 | 尿频或尿失禁的治疗或预防剂以及具有含氮环状取代基的吗啡烷衍生物 |
| US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
| DE10259934B3 (de) | 2002-12-20 | 2004-10-14 | H.C. Starck Gmbh | Verfahren zur Herstellung von Formteilen aus Niob oder Tantal durch elektrochemisches Ätzen und so erhältliche Formteile |
| AR042815A1 (es) | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| RU2326868C2 (ru) | 2003-04-28 | 2008-06-20 | Астеллас Фарма Инк. | Производное 4,4-дифтор-1,2,2,4-тетрагидро-5н-1-бензазепина или его соль |
| US20060193825A1 (en) | 2003-04-29 | 2006-08-31 | Praecis Phamaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| US7094545B2 (en) | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| BRPI0412021A (pt) | 2003-06-30 | 2006-08-15 | Alza Corp | método para revestir microprojeções de perfuração de pele |
| EP1500390B1 (en) | 2003-07-25 | 2005-08-17 | Ferring B.V. | Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| CN1826099B (zh) | 2003-07-25 | 2010-06-09 | 凡林有限公司 | 固体剂型药物组合物及其制造方法 |
| US6930932B2 (en) | 2003-08-27 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Data signal reception latch control using clock aligned relative to strobe signal |
| AU2004285481A1 (en) | 2003-10-24 | 2005-05-12 | Alza Corporation | Apparatus and method for enhancing transdermal drug delivery |
| CN1897898A (zh) | 2003-10-24 | 2007-01-17 | 阿尔扎公司 | 用于增强透皮药物传递的预处理方法和系统 |
| WO2005044333A2 (en) | 2003-10-31 | 2005-05-19 | Alza Corporation | Self-actuating applicator for microprojection array |
| DK1530967T3 (da) | 2003-11-13 | 2006-07-03 | Ferring Bv | Blisterpakning og dertil hörende fast dosisform |
| FR2862230B1 (fr) | 2003-11-17 | 2005-12-16 | Rossignol Sa | Fixation de surf |
| US7018653B2 (en) | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
| ATE319430T1 (de) | 2003-12-29 | 2006-03-15 | Ferring Bv | Verfahren zur herstellung einer festen oralen dosierungsform von desmopressin |
| MXPA06007832A (es) | 2004-01-09 | 2007-01-26 | Johnson & Johnson | Metodo y sistema de suministro de agente transdermico asistido por frecuencia. |
| GB0406048D0 (en) * | 2004-03-18 | 2004-04-21 | Ardana Bioscience Ltd | Drug formulations |
| PL1797109T3 (pl) | 2004-09-09 | 2016-11-30 | Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania | |
| US7097776B2 (en) | 2004-10-22 | 2006-08-29 | Hewlett-Packard Development Company, L.P. | Method of fabricating microneedles |
| US20060093658A1 (en) | 2004-10-26 | 2006-05-04 | Gayatri Sathyan | Apparatus and method for transdermal delivery of desmopressin |
| CN100339081C (zh) | 2004-11-10 | 2007-09-26 | 范敏华 | 一种氯雷他定口腔崩解片剂的制备方法 |
| US20080009801A1 (en) | 2004-12-02 | 2008-01-10 | Nickel Janice H | Method for dispensing material into a drug delivery device |
| US7180274B2 (en) | 2004-12-10 | 2007-02-20 | Aimtron Technology Corp. | Switching voltage regulator operating without a discontinuous mode |
| JP2008538577A (ja) | 2005-04-22 | 2008-10-30 | ワイス | ジヒドロベンゾフラン誘導体およびその使用 |
| PE20061297A1 (es) | 2005-04-22 | 2006-12-24 | Wyeth Corp | Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c |
| US7856263B2 (en) | 2005-04-22 | 2010-12-21 | Travanti Pharma Inc. | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
| BRPI0610046A2 (pt) | 2005-04-22 | 2010-05-25 | Wyeth Corp | derivados de benzodioxano e benzodioxolano e usos destes |
| WO2006116150A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| AU2006239922A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists |
| JP2008538784A (ja) | 2005-04-24 | 2008-11-06 | ワイス | 膀胱機能を調節するための方法 |
| WO2006138719A2 (en) | 2005-06-17 | 2006-12-28 | Georgia Tech Research Corporation | Coated microstructures and method of manufacture thereof |
| WO2007002523A2 (en) | 2005-06-24 | 2007-01-04 | 3M Innovative Properties Company | Collapsible patch with microneedle array |
| WO2007021970A2 (en) | 2005-08-15 | 2007-02-22 | Praecis Pharmaceuticals, Inc. | Stable pharmaceutical formulations and methods of use thereof |
| WO2007083323A2 (en) | 2006-01-23 | 2007-07-26 | Panacea Biotec Limited. | Modified release oral dosage form comprising desmopressin |
| CA2584456C (en) | 2006-03-02 | 2008-07-22 | Ferring International Center S.A. | Composition comprising desmopressin |
| WO2007127976A2 (en) | 2006-05-01 | 2007-11-08 | Georgia Tech Research Corporation | Particle based molding |
| CA2695634C (en) | 2007-08-06 | 2018-01-23 | Serenity Pharmaceuticals Corporation | Methods and devices for desmopressin drug delivery |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| JP5151774B2 (ja) | 2008-07-29 | 2013-02-27 | 株式会社リコー | クリーニング装置、プロセスユニット及び画像形成装置 |
| US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
-
2010
- 2010-03-25 US US12/732,161 patent/US20100286045A1/en not_active Abandoned
-
2011
- 2011-03-22 JP JP2013500608A patent/JP6253977B2/ja active Active
- 2011-03-22 ES ES15184741T patent/ES2708973T3/es active Active
- 2011-03-22 HU HUE11728387A patent/HUE027417T2/en unknown
- 2011-03-22 CN CN201710490960.4A patent/CN107252474A/zh active Pending
- 2011-03-22 LT LTEP15184741.5T patent/LT3006036T/lt unknown
- 2011-03-22 CN CN201911211683.4A patent/CN110898207A/zh active Pending
- 2011-03-22 EP EP15184741.5A patent/EP3006036B1/en active Active
- 2011-03-22 EP EP11728387.9A patent/EP2550007B1/en active Active
- 2011-03-22 CN CN201610887523.1A patent/CN106924716A/zh active Pending
- 2011-03-22 CN CN2011800154945A patent/CN102821776A/zh active Pending
- 2011-03-22 SI SI201131648T patent/SI3006036T1/sl unknown
- 2011-03-22 RS RS20190058A patent/RS58224B1/sr unknown
- 2011-03-22 TR TR2019/00240T patent/TR201900240T4/tr unknown
- 2011-03-22 PL PL15184741T patent/PL3006036T3/pl unknown
- 2011-03-22 WO PCT/IB2011/001010 patent/WO2012001469A1/en not_active Ceased
- 2011-03-22 DK DK11728387.9T patent/DK2550007T3/en active
- 2011-03-22 EP EP18196338.0A patent/EP3449908A1/en not_active Withdrawn
- 2011-03-22 CA CA2793502A patent/CA2793502A1/en not_active Withdrawn
- 2011-03-22 DK DK15184741.5T patent/DK3006036T3/en active
- 2011-03-22 PT PT117283879T patent/PT2550007E/pt unknown
- 2011-03-22 PT PT15184741T patent/PT3006036T/pt unknown
- 2011-03-22 ES ES11728387.9T patent/ES2559446T3/es active Active
- 2011-03-22 PL PL11728387T patent/PL2550007T3/pl unknown
-
2013
- 2013-12-30 US US14/143,866 patent/US10137167B2/en active Active
-
2016
- 2016-04-07 JP JP2016077478A patent/JP6297616B2/ja active Active
-
2017
- 2017-12-14 JP JP2017239240A patent/JP6545778B2/ja active Active
-
2018
- 2018-10-17 US US16/162,453 patent/US11020448B2/en active Active
-
2019
- 2019-01-16 HR HRP20190104TT patent/HRP20190104T1/hr unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649615A (zh) * | 2002-05-07 | 2005-08-03 | 凡林有限公司 | 药物制剂 |
| US20030216302A1 (en) * | 2002-05-15 | 2003-11-20 | Sun Pharmaceutical Industries Limited | Stable aqueous composition of a peptide |
| CN1878563A (zh) * | 2003-11-10 | 2006-12-13 | 西摩·H·费恩 | 包含低剂量去氨加压素的药物组合物 |
| CA2724653A1 (en) * | 2008-05-21 | 2009-11-26 | Ferring International Center S.A. | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6836618B2 (ja) | 夜間頻尿によって妨げられない睡眠の初期期間を増加させるための口腔内崩壊デスモプレシン | |
| CN107252474A (zh) | 用于减少夜间排尿的去氨加压素 | |
| US20220118046A1 (en) | Methods comprising desmopressin | |
| HK1238572A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1238572B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1236847A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1236847B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1228266A1 (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1196253B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1244441A1 (en) | Desmopressin for reducing nocturnal voids | |
| HK1196253A (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1228266B (en) | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia | |
| HK1216298B (en) | Desmopressin for reducing nocturnal voids | |
| HK1179156B (en) | Desmopressin for reducing nocturnal voids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1244441 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171017 |